Featured Research

from universities, journals, and other organizations

New Cost-effective Treatment For Drug-resistant Typhoid

Date:
June 27, 2007
Source:
Wellcome Trust
Summary:
New research has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organization. The study has implications for the treatment of typhoid particularly in areas where drug resistance is a major problem.

New research carried out by researchers in Nepal has shown that a new and affordable drug, Gatifloxacin, may be more effective at treating typhoid fever than the drug currently recommended by the World Health Organisation. The study, funded by the Wellcome Trust, has implications for the treatment of typhoid particularly in areas where drug resistance is a major problem.

Enteric fever, of which typhoid fever is the most common form, is a major disease affecting the developing world, where sanitary conditions remain poor. The best global estimates are of at least 22 million cases of typhoid fever each year with 200,000 deaths. Drug resistance is becoming a major problem and treatment is becoming increasingly difficult, leading to patients taking longer to recover, suffering more complications and continuing to spread the disease to their family and to their community.

Clinical investigators based at Patan Hospital Lalitpur in Kathmandu, Nepal, and the Oxford University Clinical Research Unit in Vietnam have completed a study to see if they can improve the treatment for patients with typhoid fever. Kathmandu has been termed the typhoid fever capital of the world as a result of this disease remaining so common.

"Typhoid fever is a major problem in Nepal and in the developing world and drug-resistant strains are making it even more difficult to tackle," says Dr Buddha Basnyat, senior investigator on the study. "The currently recommended treatment, Cefixime, is relatively expensive and must be administered for a longer duration than is ideal. Clearly there is an urgent need for a treatment that is cost-effective and easy to administer."

The results of the study show that a cost-effective new fluoroquinolone drug, Gatifloxacin, may be a better treatment for enteric fever than Cefixime, which is currently recommended by the World Health Organisation. In addition, Salmonella enterica Typhi and Salmonella enterica serovar Paratyhpi A, the two most common bacteria to cause enteric fever, do not show resistance to Gatifloxacin, unlike for other fluoroquinolones.

"We have shown that Gatifloxacin may be better than an established drug used by many doctors around the world," says Dr Basnyat. "There is currently no resistance to the drug, and at just over US$1 dollar for a seven day treatment course is relatively inexpensive."

"This is an important study with major implications for treating disease widespread in the developing world," says Professor Jeremy Farrar from the Oxford University Clinical Research Unit in Vietnam. "It also shows the major contribution that clinical investigators in Nepal, with the experience and knowledge gained from access to thousands of patients, can help make to improving treatment for our patients and to global health."

The full study is published in the open access journal PLoS ONE.


Story Source:

The above story is based on materials provided by Wellcome Trust. Note: Materials may be edited for content and length.


Cite This Page:

Wellcome Trust. "New Cost-effective Treatment For Drug-resistant Typhoid." ScienceDaily. ScienceDaily, 27 June 2007. <www.sciencedaily.com/releases/2007/06/070626211740.htm>.
Wellcome Trust. (2007, June 27). New Cost-effective Treatment For Drug-resistant Typhoid. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2007/06/070626211740.htm
Wellcome Trust. "New Cost-effective Treatment For Drug-resistant Typhoid." ScienceDaily. www.sciencedaily.com/releases/2007/06/070626211740.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins